AXGT - Axovant Gene Therapies Ltd.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.0800
-0.0800 (-6.90%)
At close: 4:00PM EDT

1.0600 -0.02 (-1.85%)
After hours: 6:38PM EDT

Stock chart is not supported by your current browser
Previous Close1.1600
Open1.1500
Bid1.0700 x 800
Ask1.1000 x 1000
Day's Range1.0600 - 1.1500
52 Week Range0.9300 - 2.4500
Volume832,259
Avg. Volume2,446,304
Market Cap196.818M
Beta (3Y Monthly)2.08
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire10 days ago

    Axovant Announces Upcoming Presentations at the Annual Meeting of the American Society of Gene and Cell Therapy

    -Details from ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD and the AXO-AAV-GM2 program to be featured in oral presentations- -Preclinical data from AXO-AAV-GM1 program to.

  • GlobeNewswire21 days ago

    Axovant Announces Plan to Effect Reverse Share Split

    Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announced that its Board of Directors and a majority of its shareholders have approved a reduction of issued and outstanding common shares on a 1-for-8 basis that is expected to become effective in May 2019. The reverse share split will reduce the number of common shares issued and outstanding from approximately 182.2 million common shares to approximately 22.8 million, based on shares outstanding as of March 31, 2019. The Company also noted the closing of the public offering of common shares in March 2019 for gross proceeds of $40 million with participation from leading institutional shareholders.

  • GlobeNewswire28 days ago

    Axovant Announces Clinical Updates from AXO-AAV-GM2 and AXO-Lenti-PD Studies

    Axovant Gene Therapies Ltd. (AXGT), a clinical-stage company developing innovative gene therapies, today announced additional data and plans for the AXO-AAV-GM2 and AXO-Lenti-PD programs, which will be highlighted at the Company’s R&D day for investors and analysts.

  • ACCESSWIRElast month

    Axovant Sciences Gene Therapy Showing Progress, Pipeline Review

    NEW YORK, NY / ACCESSWIRE / March 18, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • GlobeNewswirelast month

    Axovant Sciences Announces Pricing of $40 Million Public Offering of Common Shares

    Axovant Sciences (AXGT) ("Axovant") today announced the pricing of its underwritten public offering of 26,666,667 of its common shares at a price to the public of $1.50 per share. Gross proceeds to Axovant from the offering are expected to be approximately $40,000,000 before deducting underwriting discounts and commissions and estimated offering expenses.  All of the common shares are being offered by Axovant. In connection with this offering, Axovant has granted the underwriters a 30-day option to purchase up to an additional 4,000,000 of its common shares on the same terms and conditions.  The offering is expected to close on March 18, 2019, subject to customary closing conditions.

  • GlobeNewswirelast month

    Axovant Sciences Announces Public Offering of Common Shares

    Axovant Sciences (AXGT) ("Axovant") today announced that it has commenced an underwritten public offering of its common shares. All of the common shares are being offered by Axovant. In connection with this offering, Axovant expects to grant the underwriters a 30-day option to purchase additional common shares in the offering on the same terms and conditions.

  • ACCESSWIRElast month

    Four Healthcare Stocks Making Moves on Monday

    CORAL GABLES, FL / ACCESSWIRE / March 11, 2019 / The future of the healthcare stock market, and the medical sector in its entirety, is largely dependent on whether medical experts and healthcare professionals are aptly prepared to meet the growing demands of patients. As companies in the healthcare sector work to develop innovative technologies for their patients, these efforts may create potential opportunities for investors looking to the industry. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Axovant Sciences Ltd (AXGT), Tonix Pharmaceuticals Holding Corp (TNXP), and Cellect Biotechnology Ltd (APOP) are 4 healthcare companies looking to kick off a strong week of trading.

  • GlobeNewswire2 months ago

    Axovant Announces Clinical Update From First Tay-Sachs Disease Patient Dosed With AXO-AAV-GM2 Gene Therapy

    Axovant (AXGT), a clinical-stage company developing innovative gene therapies, today reported three-month data from an investigator-initiated study administering investigational AXO-AAV-GM2 gene therapy in a patient with advanced infantile Tay-Sachs disease, a rare and fatal pediatric neurodegenerative genetic disorder characterized by impaired β-Hexosaminidase A enzyme production. AXO-AAV-GM2 is an investigational gene therapy designed to restore β-Hexosaminidase A enzyme activity in the central nervous system.

  • GlobeNewswire2 months ago

    Axovant Reports Positive Interim Results From First Cohort Of SUNRISE-PD Phase 2 Trial Of AXO-Lenti-PD Gene Therapy In Parkinson’s Disease

    Axovant (AXGT), a clinical-stage company developing innovative gene therapies, today reported 3-month data from the first dose cohort in the open-label, dose-escalation portion of the ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD for the treatment of Parkinson’s disease. The cohort consisted of two patients with advanced Parkinson’s disease who received a one-time administration of the lowest dose of AXO-Lenti-PD (4.2x106 TU). “Our focus in this first cohort of the SUNRISE-PD study was on the safety and tolerability of AXO-Lenti-PD, as well as the evaluation of efficacy using well-validated, objective measures.

  • GlobeNewswire2 months ago

    Axovant to Present at Cowen and Company 39th Annual Health Care Conference

    NEW YORK and BASEL, Switzerland, March 04, 2019 -- Axovant Sciences (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Pavan.

  • GlobeNewswire2 months ago

    Axovant to Host First R&D Day March 29, 2019

    NEW YORK and BASEL, Switzerland, Feb. 21, 2019 -- Axovant Sciences (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that it will.

  • GlobeNewswire2 months ago

    Axovant to Present at 8th Annual SVB Leerink Global Healthcare Conference

    NEW YORK and BASEL, Switzerland, Feb. 19, 2019 -- Axovant Sciences (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Pavan.